Mirum Pharmaceuticals, Inc. (MIRM) Research
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Market snapshot
- Symbol
- MIRM
- Price
- $107.13
- Day change
- +4.99%
- Market cap
- $5.4B
- P/E ratio
- -7.89x
- 52-week range
- 47.89-114.99
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 1 month
- Analyst price target
- $145.4
Recent news
- Mirum's rare liver disease drug meets main goal in mid-stage study
Mirum Pharmaceuticals said on Monday its experimental drug, volixibat, met the main goal of a mid-stage study by reducing severe itching or pruritus in patients with a type of rare liver disease.
- Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) shares are up on Monday following the announcement that the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational treatment for cholestatic pruritus in patients with primary sclerosing cholangitis.
Peer companies
Recent insider activity
- Howe Jolanda — S-Sale (2594 shares) on 2026-06-17
- Walbert Timothy P — A-Award (3772 shares) on 2026-06-15
- Walbert Timothy P — A-Award (1980 shares) on 2026-06-15
- Cardon Lon — A-Award (3772 shares) on 2026-06-15
- Cardon Lon — A-Award (1980 shares) on 2026-06-15
Open Mirum Pharmaceuticals, Inc. (MIRM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.